Literature DB >> 17719477

(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials.

James H F Rudd1, Kelly S Myers, Sameer Bansilal, Josef Machac, Ash Rafique, Michael Farkouh, Valentin Fuster, Zahi A Fayad.   

Abstract

OBJECTIVES: This study tested the near-term reproducibility of (18)fluorodeoxyglucose positron emission tomography (FDG-PET) imaging of atherosclerosis.
BACKGROUND: It is known that FDG-PET can measure inflammation within the aorta, carotid, and vertebral arteries with histologic validation in humans and animal models of disease. By tracking changes in inflammation over time, PET could be used as a surrogate marker of antiatheroma drug efficacy. However, the short-term variability and reproducibility of the technique are unknown.
METHODS: We imaged the carotid arteries and aorta in 11 subjects with FDG-PET/computed tomography twice, 14 days apart. We assessed interobserver and intraobserver agreement and interscan variability.
RESULTS: Interscan plaque FDG variability over 2 weeks was very low; intraclass correlation coefficients (ICC) ranged between 0.79 and 0.92. Interobserver agreement was high across all territories imaged except aortic arch (ICC values from 0.90 to 0.97, arch 0.71). Intraobserver agreement was high, with ICC values between 0.93 and 0.98.
CONCLUSIONS: Spontaneous change in plaque FDG uptake is low over 2 weeks, with favorable inter- and intraobserver agreement. Power calculations suggest that drug studies using FDG-PET imaging would require few subjects compared with other imaging modalities. This study strengthens the case for FDG-PET as a noninvasive plaque imaging technique.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719477     DOI: 10.1016/j.jacc.2007.05.024

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  169 in total

Review 1.  Imaging of coronary inflammation with FDG-PET: feasibility and clinical hurdles.

Authors:  Ian S Rogers; Ahmed Tawakol
Journal:  Curr Cardiol Rep       Date:  2011-04       Impact factor: 2.931

2.  Monitoring anti-inflammatory therapies in patients with atherosclerosis: FDG PET emerges as the method of choice.

Authors:  M Hacker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03       Impact factor: 9.236

Review 3.  Multimodality imaging in interventional cardiology.

Authors:  Bas L van der Hoeven; Martin J Schalij; Victoria Delgado
Journal:  Nat Rev Cardiol       Date:  2012-02-14       Impact factor: 32.419

4.  (18)F-fluorodeoxyglucose PET imaging of coronary atherosclerosis and plaque inflammation.

Authors:  Wengen Chen; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

5.  PET/MRI of Hypoxic Atherosclerosis Using 64Cu-ATSM in a Rabbit Model.

Authors:  Xingyu Nie; Richard Laforest; Andrew Elvington; Gwendalyn J Randolph; Jie Zheng; Tom Voller; Dana R Abendschein; Suzanne E Lapi; Pamela K Woodard
Journal:  J Nucl Med       Date:  2016-07-07       Impact factor: 10.057

Review 6.  Cardiovascular molecular imaging: focus on clinical translation.

Authors:  Ian Y Chen; Joseph C Wu
Journal:  Circulation       Date:  2011-02-01       Impact factor: 29.690

7.  Atheroma roulette.

Authors:  H William Strauss; Jagat Narula
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

8.  Identification of inflamed atherosclerotic lesions in vivo using PET-CT.

Authors:  Mateja Kaja Jezovnik; Nina Zidar; Luka Lezaic; Borut Gersak; Pavel Poredos
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

9.  Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritis.

Authors:  Zahi A Fayad; Jeffrey D Greenberg; Jan Bucerius
Journal:  Circulation       Date:  2012-10-24       Impact factor: 29.690

10.  Dual-Modality Activity-Based Probes as Molecular Imaging Agents for Vascular Inflammation.

Authors:  Nimali P Withana; Toshinobu Saito; Xiaowei Ma; Megan Garland; Changhao Liu; Hisanori Kosuge; Myriam Amsallem; Martijn Verdoes; Leslie O Ofori; Michael Fischbein; Mamoru Arakawa; Zhen Cheng; Michael V McConnell; Matthew Bogyo
Journal:  J Nucl Med       Date:  2016-05-19       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.